Hubbry Logo
Humanized antibodyHumanized antibodyMain
Open search
Humanized antibody
Community hub
Humanized antibody
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Humanized antibody
Humanized antibody
Humanized antibody
View on Wikipedia
from Wikipedia

Humanized antibodies are antibodies from non-human species whose protein sequences have been modified to increase their similarity to antibody variants produced naturally in humans.[1][2] The process of "humanization" is usually applied to monoclonal antibodies developed for administration to humans (for example, antibodies developed as anti-cancer drugs). Humanization can be necessary when the process of developing a specific antibody involves generation in a non-human immune system (such as that in mice). The protein sequences of antibodies produced in this way are partially distinct from homologous antibodies occurring naturally in humans, and are therefore potentially immunogenic when administered to human patients (see also Human anti-mouse antibody). Until 2021, the International Nonproprietary Names of new humanized antibodies ended in -zumab, as in omalizumab, but a new nomenclature has since been adopted and new names since then end in different stems (see Nomenclature of monoclonal antibodies).

Humanized antibodies are distinct from chimeric antibodies. The latter also have their protein sequences made more similar to human antibodies, but carry a larger stretch of non-human protein.

There are other ways to develop monoclonal antibodies. This list covers many of the monoclonals developed for use in humans.

Use of recombinant DNA in humanization process

[edit]

The humanization process takes advantage of the fact that production of monoclonal antibodies can be accomplished using recombinant DNA to create constructs[3] capable of expression in mammalian cell culture. That is, gene segments capable of producing antibodies are isolated and cloned into cells that can be grown in a bioreactor such that antibody proteins produced from the DNA of the cloned genes can be harvested en masse. The step involving recombinant DNA provides an intervention point that can be readily exploited to alter the protein sequence of the expressed antibody. The alterations to antibody structure that are achieved in the humanization process are therefore all effectuated through techniques at the DNA level. Not all methods for deriving antibodies intended for human therapy require a humanization step (e.g. phage display) but essentially all are dependent on techniques that similarly allow the "insertion" or "swapping-out" of portions of the antibody molecule.

Distinction from "chimeric antibody"

[edit]
Sketches of chimeric (top right), humanized (bottom left) and chimeric/humanized (bottom middle) monoclonal antibodies. Human parts are shown in brown, non-human parts in blue.

Humanization is usually seen as distinct from the creation of a mouse-human antibody chimera. So, although the creation of an antibody chimera is normally undertaken to achieve a more human-like antibody (by replacing constant region of the mouse antibody with that from human) simple chimeras of this type are not usually referred to as humanized. Rather, the protein sequence of a humanized antibody is essentially identical to that of a human variant, despite the non-human origin of some of its complementarity-determining region (CDR) segments responsible for the ability of the antibody to bind to its target antigen.

Chimeric antibody names contain a -xi- stem. Examples of chimeric antibodies approved for human therapy include abciximab (ReoPro), basiliximab (Simulect), cetuximab (Erbitux), infliximab (Remicade) and rituximab (MabThera). There are also several examples of chimerics currently in clinical trials (e.g. bavituximab, see sortable list for additional examples).

Humanizing via a chimeric intermediate

[edit]

The humanization process may also include the creation of a mouse-human chimera as an initial step. In this case, a mouse variable region is spliced to a human constant region. The chimera can then be further humanized by selectively altering the sequence of amino acids in the variable region of the molecule.

The alteration process must be "selective" to retain the specificity for which the antibody was originally developed. That is, since the CDR portions of the variable region are essential to the ability of the antibody to bind to its intended target, the amino acids in these portions cannot be altered without the risk of undermining the purpose of the development. Aside from the CDR segments, the portions of the variable regions that differ from those in humans can be corrected by exchanging the appropriate individual amino acids. This is accomplished at the DNA level through mutagenesis.

Naming of humanized chimeras includes the stem for both designations (-xi- + -zu-). Otelixizumab is an example of a humanized chimera currently in clinical trials for treatment of rheumatoid arthritis and diabetes mellitus.[4]

Humanization by insertion of relevant CDRs into human antibody "scaffold"

[edit]

It is possible to produce a humanized antibody without creating a chimeric intermediate. "Direct" creation of a humanized antibody can be accomplished by inserting the appropriate CDR coding segments (so-called 'donor', responsible for the desired binding properties) into a human antibody "scaffold" (so-called 'acceptor'). As discussed above, this is achieved through recombinant DNA methods using an appropriate vector[3] and expression in mammalian cells. That is, after an antibody is developed to have the desired properties in a mouse (or other non-human), the DNA coding for that antibody can be isolated, cloned into a vector and sequenced (or the DNA can be sequenced directly using single-cell methods). The DNA sequence corresponding to the antibody CDRs can then be determined. Once the precise sequence of the desired CDRs are known, a strategy can be devised for inserting these sequences appropriately into a construct containing the DNA for a human antibody variant.[5][6][7][8][9] The strategy may also employ synthesis of linear DNA fragments based on the reading of CDR sequences. The process requires computer-modelling software to determine which of the antibody's amino acids can be changed from murine-sequence to human-sequence without the changes compromising the conformation of the binding site. In the United States, this software was developed, patented, and demonstrated, by Protein Design Labs, Inc. in Mountain View, California, in the 1980s and 1990s.[10]

Alemtuzumab is an early example of an antibody whose humanization did not include a chimeric intermediate. In this case, a monoclonal dubbed "Campath-1" was developed to bind CD52 using a mouse system. The hypervariable loops of Campath-1 (that contain its CDRs and thereby impart its ability to bind CD52) were then extracted and inserted into a human antibody framework.[1] Alemtuzumab is approved for treatment of B-cell chronic lymphocytic leukemia[11] and is currently in clinical trials for a variety of other conditions including multiple sclerosis.[12]

Derivation from sources other than mice

[edit]

There are technologies that completely avoid the use of mice or other non-human mammals in the process of discovering antibodies for human therapy. Examples of such systems include various "display" methods (primarily phage display) as well as methods that exploit the elevated B-cell levels that occur during a human immune response.

Display methods

[edit]

These employ the selective principles of specific antibody production but exploit micro-organisms (as in phage display) or even cell free extracts (as in ribosome display). These systems rely on the creation of antibody gene "libraries" which can be wholly derived from human RNA isolated from peripheral blood. The immediate products of these systems are antibody fragments, normally Fab or scFv.

This means that, although antibody fragments created using display methods are of fully human sequence, they are not full antibodies. Therefore, processes in essence identical to humanization are used to incorporate and express the derived affinities within a full antibody.

Adalimumab (Humira) is an example of an antibody approved for human therapy that was created through phage display.[13][14]

Antibodies from human patients or vaccine recipients

[edit]

It is possible to exploit human immune reaction in the discovery of monoclonal antibodies. Simply put, human immune response works in the same way as that in a mouse or other non-human mammal. Therefore, persons experiencing a challenge to their immune system, such as an infectious disease, cancer or a vaccination are a potential source of monoclonal antibodies directed at that challenge. This approach seems especially apt for the development of anti-viral therapies that exploit the principles of passive immunity. Variants of this approach have been demonstrated in principle[15] and some are finding their way into commercial development.[16]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Humanized antibody

View on Grokipedia
from Grokipedia
A humanized antibody is a type of engineered in which the complementarity-determining regions (CDRs) of the variable domains from a non-human source, typically a , are grafted onto a human framework to reduce while maintaining the original antigen-binding specificity. This process, known as CDR grafting, replaces the majority of the non-human sequences with human ones to minimize the risk of eliciting an anti- in patients upon repeated administration. Humanized antibodies represent an advancement over earlier murine and chimeric antibodies, which often triggered strong () responses that limited their therapeutic and safety. The development of humanized antibodies began in the late , driven by the need to create safer biologics for clinical use, with the pioneering CDR grafting technique introduced by researchers such as Greg Winter and colleagues. The first humanized approved by the U.S. (FDA) was (Zenapax), an anti-CD25 antibody for preventing acute organ , in 1997. Since then, numerous humanized antibodies have gained approval, including (Herceptin) for HER2-positive , (Xolair) for allergic , and (Campath) for and . These therapeutics target a range of conditions, such as cancers, autoimmune disorders, and inflammatory diseases, by modulating immune responses, blocking growth factors, or neutralizing pathogens. Despite their reduced immunogenicity compared to non-human antibodies, humanized antibodies can still provoke anti-drug antibodies (ADAs) in some patients due to residual non-human sequences or unique human-like motifs, prompting ongoing research into fully human and bispecific formats. Advances in computational and have further optimized humanization strategies to enhance stability, efficacy, and manufacturability. Today, humanized antibodies form a cornerstone of modern biopharmaceuticals, with more than 60 approved worldwide as of 2024, underscoring their transformative impact on precision medicine.

Definition and Background

Definition of Humanized Antibodies

Humanized antibodies are monoclonal antibodies engineered from non-human sources, typically murine, by incorporating human amino acid sequences while preserving the -binding specificity through the retention of complementarity-determining regions (CDRs). These CDRs, which form the hypervariable loops responsible for recognition, are grafted from the original non-human variable domains into human antibody frameworks. Structurally, antibodies consist of variable regions that determine specificity and constant regions that mediate effector functions; in humanized versions, regions retain the non-human CDRs but replace approximately 90-95% of the surrounding framework regions with human equivalents, leaving the constant regions fully human. This results in a where only the critical binding elements remain , minimizing alterations to the overall architecture. The primary purpose of humanization is to reduce in therapeutic applications for humans, particularly by mitigating (HAMA) responses that can neutralize the or cause adverse effects. This engineering preserves the binding affinity and functional efficacy of the original , enabling repeated dosing without eliciting strong immune rejection. The basic process begins with a non-human , followed by identification of the key CDRs in its variable domains, which are then grafted onto selected human scaffolds to form the humanized construct. This approach builds on earlier chimeric antibodies, which replace only the constant regions with human sequences, by further humanizing the variable regions.

Historical Development

The development of monoclonal antibodies (mAbs) began with the invention of hybridoma technology by Georges Köhler and César Milstein in 1975, which enabled the production of murine mAbs for research and potential therapeutic use. This breakthrough, awarded the Nobel Prize in Physiology or Medicine in 1984, facilitated the generation of specific antibodies against various targets, but early clinical applications in the 1980s revealed significant immunogenicity challenges. For instance, the first FDA-approved mAb, muromonab-CD3 (OKT3), a murine antibody used for acute transplant rejection starting in 1986, induced human anti-mouse antibody (HAMA) responses in over 80% of patients, limiting its efficacy and repeat dosing due to immune neutralization and allergic reactions. To address these immunogenicity issues, researchers introduced chimeric antibodies in the mid-1980s by fusing murine variable regions with human constant regions, reducing foreign protein content and risk. The foundational work was reported by Sherie L. Morrison and colleagues in 1984, demonstrating functional chimeric antibodies with preserved antigen-binding activity. Building on this, Michael Neuberger and colleagues in 1985 produced recombinant chimeric antibodies, including an anti-CD3 variant, which further paved the way for humanization by minimizing murine sequences while maintaining therapeutic potential. The key advancement in humanization came in 1986 with the introduction of (CDR) grafting by Peter T. Jones and colleagues, including , who reshaped a anti-lysozyme by transplanting its CDRs onto frameworks, reducing non-human sequences to less than 10% and retaining binding affinity. This technique was further applied in 1988 by Leonie Riechmann, Michael Clark, Herman Waldmann, and , who used CDR grafting on a murine anti-lysozyme . In 1989, Cary Queen and colleagues applied CDR grafting to create a humanized anti-interleukin-2 receptor (anti-Tac), optimizing framework residues for improved stability and reduction. These methods marked a shift toward more human-like antibodies suitable for chronic therapies. By the 1990s, humanized antibodies progressed to clinical approval, with (a humanized anti-CD25 mAb derived from anti-Tac) becoming the first FDA-approved in 1997 for preventing acute kidney transplant rejection. This was followed in 1998 by (Herceptin), the first humanized mAb for cancer treatment, targeting HER2 in and demonstrating reduced compared to earlier chimeric antibodies like rituximab (approved 1997). Into the , the field proliferated with numerous approvals and further refinements using computational modeling to select optimal human frameworks, enhancing affinity and manufacturability while minimizing immune responses.

Distinction from Chimeric Antibodies

Chimeric antibodies are engineered by fusing the complete variable regions (V_H and V_L) derived from non-human sources, such as mice, with human constant regions, resulting in an overall sequence that is approximately 65-70% . This construction retains the full non-human variable domains, which comprise about 30% of the antibody's total length and are responsible for binding. In distinction, humanized antibodies minimize non-human content by grafting only the complementarity-determining regions (CDRs)—typically 5-10% of the sequence—onto human variable frameworks, achieving 90-95% human sequence identity. This targeted approach contrasts with the chimeric strategy's retention of entire non-human variable regions, leading to substantially lower for humanized antibodies; for instance, chimeric antibodies provoke anti-antibody responses in 10-50% of patients, whereas humanized ones elicit such responses in fewer than 5%. An illustrative example is the chimeric (Remicade), approved in 1998, which induces human anti-chimeric antibodies in approximately 13% of patients, compared to the humanized , which demonstrates markedly reduced immunogenicity rates. Chimeric antibodies frequently act as a transitional intermediate in humanization pipelines, enabling initial testing of specificity before further refinement to humanized forms for enhanced clinical tolerance, though direct humanization techniques are increasingly favored to bypass this step.

Relation to Fully Human Antibodies

Fully human antibodies are monoclonal antibodies generated entirely from immunoglobulin sequences, without any components, typically through methods such as transgenic mice expressing antibody loci, of antibody libraries, or isolation and cloning of B cells from immunized donors. In contrast, humanized antibodies are derived from (often murine) parental antibodies, where only the complementarity-determining regions (CDRs) are grafted onto framework regions to confer specificity while minimizing foreign elements. This fundamental difference in origin allows fully human antibodies to be developed de novo from genetic material, as exemplified by produced via libraries or from transgenic mouse platforms like XenoMouse. The generation of humanized antibodies leverages existing non-human antibodies with proven binding affinity, enabling a more rapid engineering process compared to the de novo selection required for fully human antibodies, which can involve extensive library screening or animal immunization cycles. However, fully human approaches, such as human B-cell isolation for antibodies like mAb114 against , ensure complete human sequence identity from the outset, potentially reducing development risks associated with non-human backbones, though both may require subsequent optimizations for stability or expression in cell lines like . Humanized antibodies often necessitate minor adjustments to the human framework to accommodate the grafted CDRs and maintain functionality, whereas fully human antibodies avoid such adaptations entirely. In terms of , fully human antibodies exhibit near-zero risk of () responses due to the absence of non-human sequences, though they can still elicit anti-drug antibodies (ADAs) at rates of 2–89% in some cases, primarily from T-cell epitopes in the CDR regions. Humanized antibodies achieve very low —significantly reduced from chimeric antibodies (around 9% marked ADA response versus 40% for chimerics)—but retain a slightly higher potential for ADAs if the murine-derived CDRs contain immunogenic epitopes, as residual immunogenicity often resides in these CDR sequences. Both types generally provoke fewer immune responses than earlier chimeric antibodies, which retain entire non-human variable regions. Humanized antibodies are preferred when adapting established non-human monoclonal antibodies for therapeutic use, particularly for rare where prior affinity data accelerates development and reduces costs, as seen in applications. Fully human antibodies are favored for novel in chronic or repeated-dose therapies, where eliminating any residual risk is paramount to ensure long-term efficacy and , and as of early 2025, they account for approximately 35% of FDA-approved monoclonal antibodies compared to about 49% for humanized ones.

Core Humanization Techniques

CDR Grafting into Human Frameworks

CDR grafting, also known as (CDR) replacement, represents the foundational method for humanizing monoclonal antibodies by transplanting the antigen-binding loops from a non-human donor antibody into the structural framework of a human acceptor antibody, thereby minimizing while preserving functionality. This approach was first demonstrated in 1986, where murine CDRs were successfully grafted into human frameworks to produce antibodies with retained antigen specificity. The CDRs consist of six hypervariable loops—three in the heavy chain (CDR-H1, CDR-H2, CDR-H3) and three in the light chain (CDR-L1, CDR-L2, CDR-L3)—that form the for recognition. These regions are delineated using established numbering schemes, such as Kabat, which identifies CDRs based on sequence variability and positional conservation across , or Chothia, which refines boundaries according to the three-dimensional loop conformations observed in crystal structures. In contrast, the four framework regions (FR1–FR4) in each chain provide the beta-sheet scaffold that positions and stabilizes the CDRs, ensuring proper folding and overall architecture. The humanization process via CDR grafting involves several sequential steps. First, the CDRs of the non-human parent antibody are identified and sequenced through molecular cloning and sequencing techniques. Next, homologous human germline variable region genes are selected as acceptor frameworks, prioritizing those with the highest sequence identity (typically >70%) to the donor to minimize structural disruptions. The CDRs are then grafted into these human frameworks using or gene synthesis, followed by expression in mammalian cells to produce the initial humanized variant. To address potential loss of binding affinity, which can range from 10- to 100-fold due to mismatches in framework-CDR interactions, targeted back-mutations are introduced—reverting 5 to 20 key residues in the human frameworks to their original non-human counterparts, particularly in the Vernier zone that influences CDR conformation. Computational tools play a critical role in optimizing the grafted antibody. Homology modeling software, leveraging crystal structures from the (PDB), simulates the three-dimensional structure to identify framework residues that contact the CDRs or , guiding the selection of back-mutations and predicting affinity impacts. This modeling mitigates risks of conformational changes that could impair binding. Recombinant DNA technologies facilitate the precise insertion of grafted sequences into expression vectors for validation. A prominent example is (Herceptin), developed for HER2-positive , where the CDRs from the murine anti-HER2 4D5 were grafted into human IgG1 heavy and light chain frameworks. Initial grafting resulted in reduced affinity (Kd ≈ 25 nM versus 0.30 nM for the parent), but iterative back-mutations—guided by molecular modeling—yielded a variant with Kd ≈ 0.10 nM, exceeding the original by threefold while enhancing effector functions. With proper optimization, CDR grafting achieves high success rates, often retaining over 80% of the parent antibody's binding affinity, as evidenced by studies where 91% of grafts maintained functional potency against targets like LAG-3. This method's efficacy has led to its widespread adoption in generating therapeutic humanized antibodies with low and potent clinical activity.

Humanization via Chimeric Intermediates

Humanization via chimeric intermediates begins with the construction of a chimeric antibody, in which the variable (V) regions derived from a non-human —typically murine—are fused to human constant (C) regions using techniques. This intermediate form replaces the immunogenic non-human constant domains, which mediate effector functions and , with their human counterparts, thereby reducing the risk of () responses while preserving the antigen-binding specificity of the original V regions. The chimeric antibody serves as a functional for initial and testing of binding affinity, stability, and , providing a baseline for further refinement. Once validated, the V regions of the chimeric intermediate undergo targeted modifications to achieve full humanization, primarily through (CDR) grafting or related methods. In CDR grafting, the six CDRs from the non-human V domains are transplanted onto selected human framework regions, with minimal back-mutations to critical framework residues that support CDR conformation and contact. Specific techniques such as framework shuffling may follow chimerization; this involves creating libraries of the fixed non-human CDRs paired with diverse human framework combinations, followed by screening for optimal binding variants via or yeast surface expression. For instance, framework shuffling applied to the anti-EphA2 murine B233 produced fully humanized IgG variants with dissociation constants of 3–48 nM, retaining biochemical activity comparable to the parental within a 5-fold range. This multi-step pathway offers advantages including simplified initial production in mammalian expression systems, stepwise immunogenicity reduction that allows monitoring of anti-drug antibody development, and the opportunity for early optimization of and effector functions like (ADCC). A seminal example is the humanization of the murine anti-epidermal receptor 425, where the chimeric intermediate confirmed binding before CDR grafting yielded a reshaped version with approaching that of the original, highlighting the role of framework residues in maintaining loop conformation. However, chimeric intermediates still contain substantial non-human framework sequences in the V regions, resulting in residual immunogenicity that can elicit human anti-chimeric antibody (HACA) responses, often requiring extensive , library screening, and affinity maturation to mitigate. This additional complexity can prolong development timelines and risk minor losses in specificity or stability if framework compatibility is suboptimal.

Advanced and Alternative Methods

Use of Recombinant DNA Technologies

Recombinant DNA technologies form the backbone of humanized antibody construction, enabling the precise manipulation and assembly of genetic elements to reduce while preserving antigen-binding affinity. (PCR) amplification is a foundational technique for isolating complementarity-determining regions (CDRs) and variable (V) regions from non-human antibodies, allowing for their subsequent integration into human frameworks. This process typically involves designing oligonucleotide primers specific to the V gene sequences to amplify the desired fragments from cDNA or genomic DNA templates, facilitating efficient without the need for extensive library construction. further refines these constructs by introducing targeted nucleotide changes to replace non-human framework residues with human counterparts, minimizing potential immunogenic epitopes while optimizing stability and function. These mutagenesis methods, often employing overlap extension PCR or commercial kits, allow for the creation of variant libraries to fine-tune antibody properties. The cloning process begins with the ligation of humanized V genes to human constant region genes, typically using restriction enzymes to generate compatible overhangs on the DNA fragments and T4 DNA ligase to join them into a cohesive expression cassette. This assembly is inserted into mammalian expression vectors, such as those based on cytomegalovirus (CMV) promoters, which are then transfected into host cells like Chinese hamster ovary (CHO) cells for recombinant production. Transient transfection, using methods like electroporation or lipid-based reagents, enables rapid assessment of antibody expression, often yielding 0.5–2 g/L in optimized systems within 7–14 days post-transfection. For large-scale manufacturing, stable transfection integrates the vector into the host genome via selection markers (e.g., dihydrofolate reductase or glutamine synthetase), achieving higher yields of 1–5 g/L through fed-batch cultivation and clone selection. These techniques support the production of fully assembled humanized immunoglobulins, as applied in CDR grafting to transfer binding sites onto human scaffolds. Advancements in the 1990s included the adaptation of yeast artificial chromosomes (YACs) for cloning large antibody gene clusters, enabling stable maintenance and transfer of extended DNA segments up to megabases for enhanced expression in eukaryotic systems. Post-2010s developments have incorporated CRISPR-Cas9 and related editing tools for precise mutagenesis, allowing multiplexed modifications to framework regions with minimal off-target effects and higher efficiency than traditional methods. These gene-editing approaches facilitate rapid iteration in humanization workflows, integrating seamlessly with PCR and ligation steps to generate optimized variants. Quality control is integral to ensuring the fidelity and functionality of humanized antibodies produced via these technologies. Sequence verification, typically performed by Sanger or next-generation sequencing, confirms the accuracy of CDR grafts and mutations, detecting any unintended alterations introduced during amplification or . analysis, using techniques like hydrophilic interaction liquid chromatography (HILIC) or , verifies that post-translational modifications mimic human patterns, as aberrant glycans can impact and ; for instance, ensuring low content for enhanced . These assessments, conducted at multiple stages from clone selection to final product release, uphold regulatory standards for therapeutic antibodies.

Phage Display and Other Selection Methods

is a powerful selection technique used to humanize by generating and screening large libraries of antibody variants displayed on the surface of bacteriophages, such as M13. In this method, antibody genes—often derived from non-human sources and initially humanized through techniques like CDR grafting—are fused to phage coat proteins, enabling the display of up to 10^9 to 10^11 unique variants in a single library. Affinity selection, or "panning," is performed by immobilizing the target and iteratively binding, washing, and eluting phages with progressively higher affinity, allowing the isolation of optimized human-like antibodies with reduced while maintaining or enhancing binding specificity. This approach was pioneered for rapid humanization in a 1998 study where key recognition sequences from antibodies were incorporated into human frameworks and selected via monovalent , yielding variants with improved stability and function. Beyond , yeast surface display offers an alternative for antibody humanization, particularly advantageous for ensuring proper eukaryotic folding and bond formation in antibody fragments like scFvs or Fabs. In yeast display, antibody variants are expressed as fusions to the agglutinin A protein on the surface of , with library sizes typically ranging from 10^7 to 10^9; selection involves fluorescence-activated (FACS) based on binding, enabling quantitative affinity maturation of humanized candidates. For instance, yeast display has been used to evolve humanized antibodies with up to 100-fold affinity improvements by introducing targeted mutations in framework regions post-initial humanization. display complements these by providing a fully system for ultra-large libraries exceeding 10^12 variants, where mRNA-antibody- complexes are selected against without cellular constraints, facilitating error-prone PCR for rapid evolution of humanized antibodies with enhanced affinity, such as 50- to 100-fold gains in binding strength. These display methods offer key advantages in antibody humanization by generating diversity combinatorially without relying on animal , thus accelerating the identification of low-immunogenicity variants suitable for therapeutics. For example, while fully human antibodies like were derived directly from libraries of human origin, the same platforms are routinely applied to mutate and mature partially humanized antibodies from non-human leads, restoring lost affinity during grafting. Integration of display technologies often occurs post-CDR grafting, where libraries of mutated humanized frameworks undergo rounds of selection to fine-tune binding, resulting in clinically viable molecules with affinities rivaling or surpassing parental antibodies.

Computational Humanization Approaches

Recent advances in have introduced (ML) and (AI)-driven methods as alternative strategies for antibody humanization, complementing traditional experimental techniques. These approaches leverage large datasets of antibody structures and sequences to predict optimal human framework substitutions, minimizing immunogenicity while preserving binding affinity. For instance, models trained on human antibody repertoires can design humanized variants by identifying low-risk mutations in framework regions, often achieving results comparable to CDR grafting with fewer iterations. As of 2025, tools like GLIMPSE use generative AI to humanize antibodies, enhancing affinity, cross-reactivity, and developability in silico before experimental validation. Such methods reduce the need for extensive physical libraries and mutagenesis, accelerating development timelines and lowering costs.

Sources of Antibodies for Humanization

Derivation from Non-Human Animals

The derivation of parent antibodies for humanization predominantly involves non-human animals, with mice serving as the primary source due to the pioneering developed in the 1970s. In this approach, mice are immunized with target antigens to elicit a robust , followed by the isolation of antigen-specific B cells from their spleens. These B cells are then fused with immortal myeloma cells to create hybridomas capable of producing monoclonal antibodies (mAbs) indefinitely. This method, first described by Köhler and Milstein in 1975, became the standard for generating murine mAbs starting in the 1980s, forming the basis for many early humanized therapeutic antibodies approved for clinical use. Immunization protocols typically begin with an initial intraperitoneal injection of the antigen emulsified in an adjuvant, such as Freund's complete adjuvant, to enhance immune activation, using doses of 10-100 micrograms per mouse. Booster injections, often with incomplete Freund's adjuvant, are administered every 2-4 weeks for 2-4 doses to amplify the antibody response, with serum titers monitored via enzyme-linked immunosorbent assay (ELISA) to ensure sufficient affinity. Upon achieving peak titers, the mouse spleen is harvested, and hybridoma fusion proceeds using polyethylene glycol or electrofusion, followed by HAT selection medium to eliminate unfused cells. Resulting hybridoma clones are screened for high-affinity antibodies through binding assays, prioritizing those with dissociation constants (Kd) in the nanomolar range before proceeding to humanization to mitigate immunogenicity. While mice dominate due to their well-characterized and rapid breeding, other offer advantages for broader coverage or specialized formats. Rats provide similar hybridoma-based production but with potentially higher yields for certain , often used when responses are suboptimal. Rabbits yield antibodies with diverse variable regions, enabling recognition of unique epitopes, and their mAbs are humanized via CDR grafting into human frameworks to preserve binding. Camelids, such as llamas and alpacas, produce heavy-chain-only antibodies (nanobodies) that are smaller and more ; these are humanized through framework replacement with human sequences while retaining the complementarity-determining regions (CDRs) for specificity. Murine and other non-human antibodies exhibit high in humans, often leading to responses in a significant proportion of patients upon repeated exposure, necessitating humanization to reduce this risk and extend therapeutic utility. Ethical considerations have intensified since the early 2000s, driven by the 3Rs principles (replacement, reduction, refinement), leading to stricter regulations on animal numbers—estimated at millions annually for production—and a push toward alternatives like , though animal-derived sources remain prevalent for initial discovery.

Derivation from Human Sources

Antibodies can be derived directly from sources by isolating B cells from individuals who have mounted an to specific antigens, such as through or natural . This approach involves sorting antigen-specific memory B cells or plasmablasts from peripheral blood or tissues, followed by to identify paired variable heavy (VH) and variable light (VL) chain sequences for recombinant expression. For instance, in studies of survivors, researchers have isolated hundreds of neutralizing monoclonal antibodies from convalescent patients' B cells using and single-cell RNA sequencing, requiring minimal or no further humanization due to their fully origin. Similar methods have been applied post-, where B cells from immunized donors are cultured to secrete antibodies or sequenced to recover VH/VL pairs, enabling the rapid generation of therapeutic candidates against pathogens like SARS-CoV-2. Transgenic animal models, particularly humanized mice, provide a source of fully human antibodies by engineering rodents to express fully human immunoglobulin loci, thereby producing antibodies with human sequences without the need for extensive humanization. The XenoMouse system, developed in the , replaces murine immunoglobulin genes with large segments of the human heavy and kappa light chain loci, allowing immunized mice to generate high-affinity, fully human monoclonal antibodies upon hybridoma fusion. These models have been instrumental in deriving antibodies for therapeutic use, as the resulting antibodies exhibit natural human framework regions and complementarity-determining regions (CDRs), closely mimicking those from human B cells. Synthetic antibody libraries constructed from sequences offer a non-animal-derived alternative, enabling the generation of diverse antibody candidates that bypass the need for . These libraries are built by combinatorially assembling VH and VL genes based on frameworks, with controlled variations in CDRs to simulate natural diversity, and are often displayed on phages for selection. For example, the HuCAL library uses a of -derived frameworks paired with randomized CDR cassettes, facilitating the discovery of antibodies with human-like properties without relying on donor-derived sequences. More recent iterations incorporate paired heavy-light chain libraries from synthetic mimics to enhance functionality and reduce biases inherent in natural repertoires. Recent advances, including AI-driven de novo antibody as of 2025, have further expanded these synthetic approaches for more efficient discovery. Deriving antibodies from sources confers advantages such as inherently lower compared to non-human origins, as the sequences align closely with the and are less likely to elicit anti-drug antibodies in patients. This reduced risk supports their application in treating infectious diseases, where rapid deployment of neutralizing antibodies is critical, as seen in responses to viral outbreaks, and in , where tolerance to self-antigens benefits from human-compatible sequences.

Therapeutic Applications and Examples

Clinical Uses

Humanized antibodies have revolutionized targeted therapies in medicine by enabling precise intervention in disease pathways while minimizing immune reactions. Their clinical utility spans multiple domains, with administration primarily via intravenous (IV) or subcutaneous (SC) routes to achieve systemic exposure. Half-life extension through Fc engineering, which optimizes binding to the neonatal Fc receptor (FcRn), supports extended circulation and reduced dosing frequency, typically ranging from 11 to 30 days. In , humanized antibodies predominantly target growth factors and receptors such as HER2 and EGFR, which drive tumor proliferation in cancers like and colorectal malignancies. By blocking these pathways, they inhibit cell signaling, promote , and enhance antibody-dependent cellular cytotoxicity (ADCC), often in combination with or . constitutes the largest segment of the therapeutic market, accounting for approximately 50% of applications and sales. For autoimmune disorders, humanized antibodies neutralize key pro-inflammatory cytokines, including TNF and IL-6, to dampen aberrant immune responses. This approach has proven effective in managing chronic conditions like and , where cytokine blockade reduces joint inflammation and skin lesions by interrupting signaling cascades that perpetuate . In infectious diseases, humanized antibodies function as neutralizing agents against viral entry and replication, targeting structures such as the RSV fusion protein or HIV envelope glycoproteins. They offer prophylactic and therapeutic benefits, particularly in vulnerable populations like infants for RSV or immunocompromised individuals for , and have emerged as critical tools in responses, including rapid deployment against novel pathogens like SARS-CoV-2. Beyond these core areas, humanized antibodies support transplantation by targeting immune activation molecules, such as IL-2 receptors or CD3, to prevent organ rejection and induce tolerance without broad immunosuppression.

Notable Humanized Antibody Drugs

Trastuzumab (Herceptin), a humanized IgG1 monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), was approved by the FDA in 1998 as the first targeted therapy for HER2-positive metastatic breast cancer. This drug revolutionized treatment for HER2-overexpressing breast cancers by binding to HER2 on tumor cells, inhibiting proliferation and inducing antibody-dependent cellular cytotoxicity. Clinical trials demonstrated that one year of adjuvant trastuzumab after chemotherapy improved disease-free survival by approximately 46% and overall survival by 37% in women with HER2-positive early-stage breast cancer. At its peak, Herceptin generated annual global sales exceeding $7 billion, underscoring its commercial and clinical impact. Omalizumab (Xolair), a humanized IgG1 targeting free (IgE), received FDA approval in 2003 for moderate-to-severe persistent inadequately controlled by inhaled corticosteroids. By blocking IgE binding to high-affinity receptors on mast cells and , it reduces allergic and asthma exacerbations. Long-term studies showed that omalizumab decreased asthma-related hospitalizations and emergency visits by up to 50% in eligible patients. Expanded approvals in 2024 extended its use to IgE-mediated food allergies in children and adults, marking it as the first for this condition. Xolair has achieved significant market penetration, with global sales surpassing $1.5 billion annually by the early . Alemtuzumab (Campath), a humanized IgG1 antibody directed against on lymphocytes and monocytes, was approved by the FDA in 2001 for B-cell (CLL) in patients treated with alkylating agents. It depletes malignant B-cells through complement-dependent and , achieving response rates of 30-40% in refractory CLL cases. Later approvals in 2014 under the name Lemtrada expanded its use to relapsing , where it reduced annualized relapse rates by 55% compared to . Despite its efficacy, alemtuzumab's market presence has been limited post-2012 due to manufacturing shifts, with peak sales around $200 million annually. Bevacizumab (Avastin), a humanized IgG1 neutralizing (VEGF-A), was approved by the FDA in 2004 for metastatic in combination with . By inhibiting , it extends in various solid tumors, including non-small cell lung cancer and , with hazard ratios for ranging from 0.54 to 0.66 across indications. Subsequent approvals broadened its use to ovarian, renal, and cervical cancers. Avastin peaked at global sales of $7.1 billion in 2019, reflecting its broad adoption before competition.

Advantages, Limitations, and Future Directions

Immunogenicity Reduction and Efficacy Benefits

Humanized antibodies substantially mitigate risks associated with their non-human predecessors, enabling safer and more effective therapeutic use. Murine monoclonal antibodies can provoke (HAMA) responses in a substantial proportion of patients, with rates varying from approximately 20% to over 80% depending on the antibody, dosing, and patient factors. In contrast, humanization significantly reduces the incidence of anti-antibody responses, such as human anti-chimeric antibodies (HACA) or human anti-human antibodies (HAHA), though rates can vary widely (0-89%) depending on the specific antibody and patient population. This lower profile supports chronic or repeated dosing regimens without significant immune-mediated loss of activity, improving patient outcomes in long-term treatments. Regarding efficacy, humanized antibodies preserve the antigen-binding specificity and affinity of the original non-human , with dissociation constants (K_D) generally in the low nanomolar range, ensuring robust target engagement comparable to parental molecules. The incorporation of a fully human Fc domain further enhances effector functions, including (ADCC) and (CDC), through optimized interactions with human Fcγ receptors on immune effector cells and the —functions poorly supported by murine Fc regions in human hosts. Key benefits of these immunological and functional improvements include extended and operational advantages in clinical settings. Humanized antibodies exhibit serum half-lives of 20-30 days, mediated by efficient via the human neonatal (FcRn), in stark contrast to the short 2-3 day half-lives of murine antibodies, which suffer from poor FcRn binding and accelerated clearance. This prolonged circulation facilitates better tissue distribution and penetration into solid tumors, where sustained exposure enhances therapeutic efficacy. Consequently, fewer administrations are required, reducing treatment costs and patient burden while maintaining or improving response rates—clinical trials in and autoimmune indications have demonstrated up to 2-5-fold higher objective response rates for humanized antibodies relative to chimeric counterparts in select cases.

Challenges in Development and Production

One of the primary technical challenges in developing humanized antibodies is the potential loss of antigen-binding affinity during the CDR grafting process, where complementarity-determining regions (CDRs) from a non-human antibody are transplanted onto a human framework, often resulting in reduced binding strength due to disrupted interactions between the CDRs and framework residues. This affinity loss is commonly addressed through back-mutations, which revert select human framework residues to their original non-human counterparts to restore functionality, but this approach relies on iterative trial-and-error testing to identify optimal sites without compromising overall humanization. Additionally, framework mismatches between the donor and acceptor sequences can increase the risk of antibody aggregation, particularly under physiological conditions or during formulation for subcutaneous delivery, potentially leading to reduced stability and heightened immunogenicity. Production of humanized antibodies faces significant hurdles related to , , and . The full development of a drug, including humanization steps, typically costs between $1 billion and $2.6 billion (capitalized). in bioreactors remains challenging, as transitioning from small-scale cultures to large-volume production (e.g., thousands of liters) can introduce variations in cell viability, nutrient gradients, and , often resulting in inconsistent yields and product quality. Furthermore, variations in patterns—such as differences in or content—arising from host cell lines like cells can alter effector functions, , and efficacy, necessitating precise control to ensure therapeutic consistency. Regulatory oversight adds complexity, with the FDA and EMA mandating comprehensive assessments, including multi-tiered anti-drug antibody (ADA) assays, to evaluate potential immune responses during preclinical and clinical phases. These requirements involve sensitive screening, confirmatory, and neutralizing antibody assays to detect ADAs that could neutralize the antibody or trigger s. Post-approval, ongoing is required to monitor rare hypersensitivities, such as or infusion reactions, with reporting integrated into labeling and risk evaluation mitigation strategies. Economically, the expiration of patents on blockbuster humanized antibodies, such as Herceptin's in 2019, has spurred development to capture , yet replicating the complex structure and manufacturing processes of originators remains technically demanding and costly due to the need for demonstrating biosimilarity in , nonclinical studies, and clinical trials. This cliff dynamic intensifies pressure on innovators to extend exclusivity through secondary patents, while biosimilar entrants face barriers like patent thickets that delay market entry. Recent advancements in humanized antibody technology are increasingly focusing on bispecific and multispecific formats that enable simultaneous targeting of multiple antigens, enhancing therapeutic precision particularly in . For instance, derivatives of , a bispecific T-cell engager, have been humanized to reduce while maintaining dual engagement of and CD3, leading to improved safety profiles in clinical trials for relapsed B-cell malignancies. As of November 2025, over 19 bispecific antibodies, many incorporating humanized scaffolds, have received regulatory approval for antitumor applications, with ongoing developments emphasizing formats like T-cell engagers and dual-affinity retargeting molecules. The integration of (AI) and (ML) is revolutionizing the humanization process by enabling predictive modeling for (CDR) optimization, which accelerates candidate selection and minimizes experimental iterations. AI-driven algorithms now predict immunogenicity risks and suggest framework substitutions with high accuracy, streamlining the grafting of murine CDRs into human backbones. These computational approaches have shortened development timelines, allowing for rapid generation of low-immunogenic variants suitable for chronic therapies. Next-generation humanized antibodies are also incorporating glycoengineering to enhance effector functions, such as (ADCC), through modifications like afucosylation that boost Fcγ receptor binding without compromising specificity. Furthermore, combinations with chimeric antigen receptor T-cell (CAR-T) therapies are emerging, where humanized antibodies serve as bridging agents to improve CAR-T infiltration and persistence in solid tumors. Market projections for antibody therapeutics, including humanized variants, indicate robust growth, with the global monoclonal antibody sector expected to reach approximately $495 billion by 2030, driven by expansions into rare diseases such as and certain genetic disorders. Innovations in delivery, including oral formulations via capsule-based systems like RaniPill, are addressing patient compliance for long-term treatments in chronic and rare conditions. Sustainability efforts are shifting production toward plant-based and microbial expression platforms, which offer lower costs and reduced environmental impact compared to traditional mammalian cell cultures; for example, tobacco-derived systems have demonstrated scalable yields for humanized antibodies. These trends underscore a move toward more efficient, accessible, and eco-friendly humanized antibody development.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC2881252/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6294595/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3011222/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC11467159/
  5. https://pubmed.ncbi.nlm.nih.gov/16324646/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC5022998/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC8760955/
  8. https://www.antibodysociety.org/resources/approved-antibodies/
  9. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/humanized-antibody
  10. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/humanized-antibody
  11. https://doi.org/10.1038/256495a0
  12. https://doi.org/10.1073/pnas.81.21.6851
  13. https://www.nature.com/articles/321522a0
  14. https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/trasgen092598lb.pdf
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC11587137/
  16. https://www.sciencedirect.com/topics/medicine-and-dentistry/chimeric-antibody
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3092621/
  18. https://www.sciencedirect.com/topics/immunology-and-microbiology/humanized-antibody
  19. https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/inflcen082498lb.pdf
  20. https://www.ncbi.nlm.nih.gov/books/NBK572118/
  21. https://www.sinobiological.com/resource/antibody-technical/chimeric-monoclonal-antibody
  22. https://www.researchgate.net/figure/The-transition-from-mouse-to-chimeric-to-humanized-and-to-human-monoclonal-antibodies_fig1_308017573
  23. https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-019-0592-z
  24. https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-025-01190-2
  25. http://www.bioinf.org.uk/abs/info.html
  26. https://www.liebertpub.com/doi/10.1089/mab.2013.0080
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC5045135/
  28. https://www.pnas.org/doi/10.1073/pnas.89.10.4285
  29. https://www.imrpress.com/journal/FBL/13/5/10.2741/2786/pdf
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC11284016/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC10805677/
  32. https://pubmed.ncbi.nlm.nih.gov/15848074/
  33. https://doi.org/10.1073/pnas.86.24.10029
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC309684/
  35. https://academic.oup.com/nar/article-pdf/19/9/2471/7075442/19-9-2471.pdf
  36. https://pubmed.ncbi.nlm.nih.gov/7821819/
  37. https://www.sciencedirect.com/science/article/pii/S0021925818407417
  38. https://www.nature.com/articles/srep05885
  39. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2022.856049/full
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC8959507/
  41. https://www.sciencedirect.com/science/article/pii/S2472555222072197
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC3522797/
  43. https://bmcbiotechnol.biomedcentral.com/articles/10.1186/s12896-019-0504-z
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC6816377/
  45. https://pubs.acs.org/doi/10.1021/jasms.0c00432
  46. https://www.nature.com/articles/s41598-022-19488-8
  47. https://www.sciencedirect.com/science/article/pii/S135964461600026X
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC21176/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC4544684/
  50. https://www.pnas.org/doi/10.1073/pnas.95.24.14130
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC4457833/
  52. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01986/full
  53. https://www.sciencedirect.com/science/article/abs/pii/S0167779906002381
  54. https://www.biorxiv.org/content/10.1101/2025.06.08.658113v1
  55. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1399438/full
  56. https://www.mdpi.com/1422-0067/26/18/8794
  57. https://www.euromabnet.com/protocols/immunization.php
  58. https://www.thermofisher.com/us/en/home/life-science/antibodies/custom-antibodies/custom-antibody-production/custom-monoclonal-antibody-production.html
  59. https://oacu.oir.nih.gov/system/files/media/file/2021-02/b10_ascites_guide_archive.pdf
  60. https://www.lifearc.org/what-we-do/science/antibody-humanization/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC5384799/
  62. https://absoluteantibody.com/prometheus-2-0/
  63. https://www.nature.com/articles/s41573-011-0004-z
  64. https://www.biointron.com/blog/The-Ethics-of-Antibody-Production-in-Animals-for-Research.html
  65. https://www.nature.com/articles/s41591-020-0998-x
  66. https://www.nature.com/articles/s41421-021-00340-8
  67. https://www.nature.com/articles/s41467-022-35781-6
  68. https://pubmed.ncbi.nlm.nih.gov/17921999/
  69. https://www.sciencedirect.com/science/article/abs/pii/S0022283699934447
  70. https://www.nature.com/articles/s41586-023-06681-9
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC4169037/
  72. https://www.nature.com/articles/s41573-022-00495-3
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC6923804/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC3327515/
  75. https://www.nejm.org/doi/full/10.1056/NEJMoa052306
  76. https://www.aacr.org/blog/2023/10/17/25-years-of-trastuzumab-a-legacy-of-innovation/
  77. https://www.ncbi.nlm.nih.gov/books/NBK545183/
  78. https://www.xolairhcp.com/allergic-asthma/efficacy/clinical-trial-information.html
  79. https://www.novartis.com/us-en/news/media-releases/fda-approves-xolair-omalizumab-first-and-only-medicine-children-and-adults-one-or-more-food-allergies
  80. https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/alemmil050701LB.htm
  81. https://clinimmsoc.org/Table-of-Compounds/Alemtuzumab.htm
  82. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/avastin-bevacizumab-information
  83. https://www.pharmaceutical-technology.com/analyst-comment/oncology-biosimilar-case-studies-bevacizumab/
  84. https://www.researchgate.net/post/What-is-the-common-KD-range-for-antigen-antibody-binding
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC2769226/
  86. https://academic.oup.com/proteincell/article/9/1/15/6768236
  87. https://www.nature.com/articles/nrd3003
  88. https://www.tandfonline.com/doi/abs/10.3109/10428199809059217
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC5058614/
  90. https://www.oncotarget.com/article/17228/text/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC9847343/
  92. https://csdd.tufts.edu/tufts-csdd-tdf-study
  93. https://www.susupport.com/blogs/knowledge/challenges-in-monoclonal-antibody-production
  94. https://www.sciencedirect.com/science/article/abs/pii/S0022354915300939
  95. https://www.fda.gov/media/119788/download
  96. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf
  97. https://www.fda.gov/media/155871/download
  98. https://www.fiercepharma.com/special-report/top-pharma-patent-expirations-2019
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC9439849/
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC12320366/
  101. https://www.biochempeg.com/article/431.html
  102. https://www.tandfonline.com/doi/full/10.1080/19420862.2024.2443538
  103. https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-025-01141-x
  104. https://www.biorxiv.org/content/10.1101/2025.03.09.641110v1
  105. https://www.biointron.com/antibody-industry-trends/january-2025-antibody-glycoengineering.html
  106. https://www.nature.com/articles/s41392-025-02269-w
  107. https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market
  108. https://www.chugai-pharm.co.jp/english/news/detail/20251020083000_1181.html
  109. https://www.genscript.com/learning-center/antibody-drugs-market-analysis-and-future-trends.html
Add your contribution
Related Hubs
User Avatar
No comments yet.